{"id":530463,"date":"2021-02-16T14:58:01","date_gmt":"2021-02-16T14:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=530463"},"modified":"2021-02-16T14:58:01","modified_gmt":"2021-02-16T14:58:01","slug":"presbyopia-market-size-share-competitive-analysis-market-research-and-forecast-report-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/presbyopia-market-size-share-competitive-analysis-market-research-and-forecast-report-2030_530463.html","title":{"rendered":"Presbyopia Market Size, Share, Competitive Analysis, Market Research and Forecast Report 2030"},"content":{"rendered":"
\"Presbyopia<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight launched a new report on Presbyopia Market Insights, Epidemiology and Market Forecast 2030<\/a>.<\/strong><\/p>\n

DelveInsight’s “Presbyopia Market Report 2030<\/a>“<\/strong> delivers an in-depth understanding of the Presbyopia , historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Presbyopia <\/strong>is the normal loss of near focusing ability that occurs with age. Most people begin to notice the effects of presbyopia sometime after age 40. It is a result of a gradual decrease in accommodative amplitude, from about 15 diopters (D) to 1 D. This typically comes on between the ages of 40 and 60 as the lenses of the eyes naturally lose elasticity due to the ageing process.<\/p>\n

\"\"<\/p>\n

View our detailed report: https:\/\/www.delveinsight.com\/report-store\/presbyopia-market<\/span><\/a><\/strong><\/p>\n

Presbyopia can be classified by type which includes:<\/strong><\/p>\n

1. Incipient presbyopia<\/p>\n

2. Functional presbyopia<\/p>\n

3. Absolute presbyopia<\/p>\n

4. Premature presbyopia<\/p>\n

5. Nocturnal presbyopia<\/p>\n

Symptoms<\/strong>:<\/p>\n

1. Delays in focusing at near or distance<\/p>\n

2. Ocular discomfort<\/p>\n

3. Headache<\/p>\n

4. Asthenopia<\/p>\n

5. Squinting<\/p>\n

6 Fatigue<\/p>\n

7. Need for brighter light for reading<\/p>\n

8. Diplopia<\/p>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/presbyopia-market<\/span><\/a><\/strong><\/p>\n

“According to the research study of He et al. (2012), the prevalence rate of presbyopia was approximately 83% in the case of the United States.”<\/strong><\/p>\n

Market Insights:<\/strong><\/p>\n

There is a high unmet need for new therapies. There are currently no FDA-approved drugs for the treatment of presbyopia. Different approaches on the cornea and the crystalline lens are being pursued to achieve surgical correction of this disability. However, several limitations and considerations have prevented widespread acceptance of surgical correction for presbyopia. The quality of vision, optical and visual distortions, regression of effect, complications such as corneal ectasia and haze, anisometropia after monovision correction, impaired distance vision, and the invasive nature of the current techniques have limited the utilization of presbyopia surgery. Also, the standard-of-treatment is the use of reading glasses, which can be quickly misplaced, damaged, or broken. Glasses for reading must be regularly changed as presbyopia progresses.<\/p>\n

Key companies:<\/strong><\/p>\n

1. Orasis Pharmaceuticals Ltd<\/p>\n

2. Allergan<\/p>\n

3. Novartis Pharmaceuticals<\/p>\n

Click here and download a detailed sample copy of the report.<\/strong><\/a><\/p>\n

Table of contents<\/strong><\/p>\n

1 Key Insights
2 Executive Summary of Presbyopia
3 Presbyopia Market Overview at a Glance
4 Disease Background and Overview: Presbyopia
5 Case Reports
6 Presbyopia Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Presbyopia Treatment and Medical Practices
11 Unmet needs
12 Presbyopia Marketed Drugs
13 Presbyopia Emerging Drugs
14 Presbyopia 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Presbyopia Market Drivers
19 Presbyopia Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance. <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-530463","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=530463"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530463\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=530463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=530463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=530463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}